

NCT02804646 comparison:

Summary:
CHIA has 2 criteria while your personal folder has 2 criteria
Total found criteria: 2/2
Total not Found: 0/2
Total Extra: 2
This trial is VALID



╒════════════════════════════════════════════════════╤════════════════════════════════════════════════════╕
│ CHIA Criteria                                      │ Matching Personal Criteria                         │
╞════════════════════════════════════════════════════╪════════════════════════════════════════════════════╡
│ histologically confirmed (patients not receiving a │ histologically confirmed (patients not receiving a │
│ single sputum cytology diagnosis) non-small cell   │ single sputum cytology diagnosis) non-small cell   │
│ lung cancer patients,with wild-type EGFR and ALK-  │ lung cancer patients,with wild-type EGFR and ALK-  │
│ negative; 2) According to IASLC2009 new TNM        │ negative; 2) According to IASLC2009 new TNM        │
│ staging of lung cancer stage <U+2162>B or          │ staging of lung cancer stage ⅢB or Ⅳ, previously   │
│ <U+2163>, previously untreated or relapsed after 1 │ untreated or relapsed after 1 year of lung cancer  │
│ year of lung cancer resection; 3) have at least    │ resection; 3) have at least one evaluable          │
│ one evaluable lesions,according to version 1.1 of  │ lesions,according to version 1.1 of the standard   │
│ the standard in accordance with a judgment         │ in accordance with a judgment RECIST(longest       │
│ RECIST(longest diameter on a spiral CT at least    │ diameter on a spiral CT at least 10mm,on a regular │
│ 10mm,on a regular CT longest diameter at least     │ CT longest diameter at least 20mm); 4) Male or     │
│ 20mm); 4) Male or female, aged 18 to 75 years; 5)  │ female, aged 18 to 75 years; 5) ECOG PS 0 or 1; 6) │
│ ECOG PS 0 or 1; 6) expected survival at least 3    │ expected survival at least 3 months; 7) adequate   │
│ months; 7) adequate hematological function:        │ hematological function: absolute neutrophil count  │
│ absolute neutrophil count (ANC) at least 2×10^9/L  │ (ANC) at least 2×10\^9/L and platelet count at     │
│ and platelet count at least 100×10^9/L and         │ least 100×10\^9/L and hemoglobin at least 9 g/dL;  │
│ hemoglobin at least 9 g/dL; 8) adequate liver      │ 8) adequate liver function: total bilirubin less   │
│ function: total bilirubin less than upper limit of │ than upper limit of normal (ULN); AST and ALT less │
│ normal (ULN); AST and ALT less than 2.5 times      │ than 2.5 times upper limit of normal (ULN);        │
│ upper limit of normal (ULN); alkaline phosphatase  │ alkaline phosphatase less than 5 times the upper   │
│ less than 5 times the upper limit of normal (ULN); │ limit of normal (ULN); 9) adequate renal function: │
│ 9) adequate renal function: serum creatinine less  │ serum creatinine less than upper limit of normal   │
│ than upper limit of normal (ULN) or calculated     │ (ULN) or calculated creatinine clearance at least  │
│ creatinine clearance at least 60 mL/min; 10) ECG   │ 60 mL/min; 10) ECG is normal, there is no non-     │
│ is normal, there is no non-healing wounds on the   │ healing wounds on the body; 11) had not received   │
│ body; 11) had not received previous treatment      │ previous treatment anticancer drugs, or had only   │
│ anticancer drugs, or had only received for         │ received for previous non-metastatic tumors        │
│ previous non-metastatic tumors adjuvant or         │ adjuvant or neoadjuvant chemotherapy, but when you │
│ neoadjuvant chemotherapy, but when you start to    │ start to study treatment has ended more than 6     │
│ study treatment has ended more than 6 months; 12)  │ months; 12) have conducted previous surgery        │
│ have conducted previous surgery patients required  │ patients required to study treatment was started   │
│ to study treatment was started more than four      │ more than four weeks, and the patient had          │
│ weeks, and the patient had recovered; 13) have an  │ recovered; 13) have an intact uterus in women      │
│ intact uterus in women prior to enrollment in the  │ prior to enrollment in the study must have a       │
│ study must have a negative pregnancy test result   │ negative pregnancy test result (unless it is       │
│ (unless it is already 24 months of amenorrhea)     │ already 24 months of amenorrhea) within 28 days.   │
│ within 28 days. If the pregnancy test from the     │ If the pregnancy test from the first               │
│ first administration more than seven days, urine   │ administration more than seven days, urine         │
│ pregnancy test is required for authentication      │ pregnancy test is required for authentication      │
│ (less than 7 days before the first dose); 14)      │ (less than 7 days before the first dose); 14)      │
│ previous to biological agents, particularly E.coli │ previous to biological agents, particularly E.coli │
│ genetically engineered products without serious    │ genetically engineered products without serious    │
│ allergic reactions; 15) signed informed consent    │ allergic reactions; 15) signed informed consent    │
├────────────────────────────────────────────────────┼────────────────────────────────────────────────────┤
│ pregnancy, breast-feeding women, or female         │ pregnancy, breast-feeding women, or female         │
│ patients of childbearing potential but did not     │ patients of childbearing potential but did not     │
│ take contraceptive measures;2) existing severe     │ take contraceptive measures;2) existing severe     │
│ acute infection and is not controlled; or purulent │ acute infection and is not controlled; or purulent │
│ and chronic infection, delayed healing wounds; 3)  │ and chronic infection, delayed healing wounds; 3)  │
│ the original severe heart disease, including       │ the original severe heart disease, including       │
│ congestive heart failure, uncontrolled high-risk   │ congestive heart failure, uncontrolled high-risk   │
│ arrhythmias, unstable angina, myocardial           │ arrhythmias, unstable angina, myocardial           │
│ infarction, severe heart valve disease and         │ infarction, severe heart valve disease and         │
│ resistant hypertension; 4) suffering from          │ resistant hypertension; 4) suffering from          │
│ neurological and psychiatric diseases or mental    │ neurological and psychiatric diseases or mental    │
│ disorders is not easy to control, poor compliance, │ disorders is not easy to control, poor compliance, │
│ and can not be described with treatment            │ and can not be described with treatment            │
│ responders; primary brain or central nervous       │ responders; primary brain or central nervous       │
│ metastasis disease has not been controlled, with   │ metastasis disease has not been controlled, with   │
│ significant cranial hypertension or                │ significant cranial hypertension or                │
│ neuropsychiatric symptoms; 5) have bleeding        │ neuropsychiatric symptoms; 5) have bleeding        │
│ tendencies; 6) other researchers believe that      │ tendencies; 6) other researchers believe that      │
│ patients should not participate in the present     │ patients should not participate in the present     │
│ trial                                              │ trial                                              │
╘════════════════════════════════════════════════════╧════════════════════════════════════════════════════╛



Everything was Found



╒═══════════════════════════════════╕
│ Extra Personal Criteria           │
╞═══════════════════════════════════╡
│ Must have maximum age of 75 Years │
├───────────────────────────────────┤
│ Must have minimum age of 18 Years │
╘═══════════════════════════════════╛